QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: jpet.108.142414v1 327/2/324    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rudolph, V. Articles by Baldus, S. Search for Related Content PubMed PubMed Citation Articles by Rudolph, V. Articles by Baldus, S.

CARDIOVASCULAR

Bivalirudin Decreases NO Bioavailability by Vascular Immobilization of Myeloperoxidase

Department of Cardiology and Angiology, Heart Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany (V.R., T.K.R., D.L., K.S., A.K., T.M., S.B.); and Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (V.R., T.K.R., F.J.S., G.B., B.A.F.)

Bivalirudin, a direct thrombin inhibitor, has emerged as an important alternative to heparin in patients undergoing percutaneous coronary intervention. However, it remains elusive if potentially adverse extracoagulant properties are responsible for the fact that its favorable effects in clinical studies are mainly driven by a reduction in bleeding events. The aim of the current study was to determine the effects and mechanisms of acute treatment with bivalirudin in comparison to heparin on NO bioavailability, an important factor for the pathogenesis of ischemic events. In particular, we studied the interaction between bivalirudin and myeloperoxidase (MPO), a leukocyte-derived enzyme that consumes endothelial-derived nitric oxide (NO), modifies a variety of biological targets, and thus affects the integrity of the vessel wall. In patients undergoing elective percutaneous coronary intervention, bivalirudin, in contrast to heparin, exhibited a significant decrease in plasma MPO levels (p = 0.03) accompanied by a deterioration of flow-mediated dilation (p = 0.02), a surrogate for endothelial NO bioavailability. In vitro experiments revealed avid binding of bivalirudin to both bovine aortic endothelial cells (BAEC) and MPO. Methylation of bivalirudin carboxyl groups at the carboxyl-terminal end revealed the specific binding site of bivalirudin to MPO. Bivalirudin-facilitated binding of MPO to BAEC resulted also in functional changes in terms of increased NO consumption as well as enhanced MPO-mediated redox modifications. These results illustrate dichotomous extracoagulant properties of heparins and thrombin inhibitors and suggest that bivalirudin acutely impairs endothelial NO bioavailability, thereby underscoring the potentially critical role of MPO as a mediator of vascular function.

Address correspondence to: Dr. Volker Rudolph, University Hospital Hamburg-Eppendorf, Heart Center, Department of Cardiology and Angiology, Martinistrasse 52, 20246 Hamburg, Germany. E-mail: v.rudolph{at}uke.unihamburg.de